A gastroenterologist’s perspective of the medical management of patients with Crohn’s disease and ulcerative colitis

  • A. B. R. Thomson

Abstract

The reasons for the chronic relapsing nature of Crohn’s disease (CD) and chronic idiopathic ulcerative colitis (UC) are unknown. Certain factors have been described in association with symptomatic recurrences, such as the use of nonsteroidal anti-inflammatory drugs (NSAID), an intercurrent viral illness, emotional stress, pregnancy, development of diarrhea masquerading as active disease in a patient on antibiotics, the rare worsening of symptoms with sulfasalazine, the discontinuation of maintenance therapy, and a change in smoking habits. It is important to establish the cause of recurrences. It is, however, recognized that many more persons will have endoscopically active CD after a previous surgical resection, than those who have symptoms (Rutgeerts et al., 1990). It is unclear whether the object of therapy should be to control symptoms or to control disease activity (as measured endoscopically, microscopically or biochemically). Knowing what are the pathophysiological factors responsible for causing the inflammation, or causing the inflammation to become symptomatic, would be useful considerations.

Keywords

Inflammatory Bowel Disease Ulcerative Colitis Elemental Diet Active Ulcerative Colitis Distal Ulcerative Colitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol. 1990; 85: 717–22.PubMedGoogle Scholar
  2. Afdhal NH, Long A, Lennon J, Crowe J, O’Donaghue DP. Controlled trial of antimyobacterial therapy in Crohn’s disease. Dig Dis Sci. 1991; 36: 449–53.PubMedCrossRefGoogle Scholar
  3. Alstead EM, Ritchie JK, Lennard-Jones JE, Farthing MUG, Lark ML. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology. 1990a; 99: 730–6.Google Scholar
  4. Alstead EM, Ritchie JK, Lennard-Jones JE, Farthing MJG, Clark ML. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology. 1990b; 99: 443–6.PubMedGoogle Scholar
  5. Angus P, Snook JA, Reid M, Jewell DP. Oral fluticasone propionate in active distal ulcerative colitis. Gut. 1992; 33: 711–14.PubMedCrossRefGoogle Scholar
  6. Arora S, Katkov WN, Cooley J et al. A double-blind, randomized, placebo-controlled trial of methotrexate in Crohn’s disease. Immunol Microbiol Inflam Disorders, 1992; A591.Google Scholar
  7. Asian A, Triadafilopoulos GL. Fish oil fatty acid supplementation in active ulcerative colitis: a double blind placebo-controlled, crossover study. Am J Gastroenterol. 1992; 87: 432–7.Google Scholar
  8. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulfasalazine. Lancet. 1977; 2: 892–5.Google Scholar
  9. Baker K, Jewell DP. Cyclosporin for the treatment of severe inflammatory bowel disease. Aliment Pharmacol Ther. 1989; 3: 143–9.PubMedCrossRefGoogle Scholar
  10. Bello C, Goldstein F, Thornton JJ. Alternate day prednisone treatment and treatment maintenance in Crohn’s disease. Am J Gastroenterol. 1991; 86: 460–6.PubMedGoogle Scholar
  11. Best WR, Becktel JM, Singleton JW, Kern FJ Jr. Development of a Crohn’s disease activity index: National Cooperative Crohn’s Disease Study. Gastroenterology. 1976; 70: 439–4.Google Scholar
  12. Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn’s disease activity index (CDAI). Gastroenterology. 1979; 77: 843–6.PubMedGoogle Scholar
  13. Bianchi Porro G, Campieri M, Bianchi P et al. Comparison of budesonide and methylprednisolone in the treatment of ulcerative colitis. Ital J Gastroenterol. 1991; 23: 640.Google Scholar
  14. Bicks RO, Groshart KD. The current status of T-lymphocyte apheresis of Crohn’s disease. J Clin Gastroenterol. 1989; 11: 136–8.PubMedCrossRefGoogle Scholar
  15. Biddle WL, Miner PB Jr. Long-term use of mesalamine enemas to induce remission in ulcerative colitis. Gastroenterology. 1990; 99: 113–18.PubMedGoogle Scholar
  16. Bjorck S, Dahlstrom A, Ahlman H. Topical treatment with lidocaine in patients with ulcerative colitis. Gastroenterology. 1991; 100: A198.Google Scholar
  17. Bondesen S and the Danish 5-ASA Group. Mesalazine (Pentasa) as prophylaxis in Crohn’s disease. A multicenter, controlled trial. Scand J Gastroenterol. 1991; 26 (Supp1.183): 68.Google Scholar
  18. Brignola C, Campieri M, Bassocchi G, Farrugia P, Tagnone A, Lanfranchi GA. A laboratory index for predicting relapse in asymptomatic patients with Crohn’s disease. Gastroenterology. 1986; 91: 1490–4.PubMedGoogle Scholar
  19. Brignola C, Campieri M, Farrugia P et al. The possible utility of steroids in the prevention of relapses of Crohn’s disease in remission: a preliminary study. J Clin Gastroenterol. 1988; 10: 631–4.PubMedCrossRefGoogle Scholar
  20. Brignola C, Iannone P, Pasquali S et al. Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn’s disease. Dig Dis Sci. 1992; 37 (1): 29–32.PubMedCrossRefGoogle Scholar
  21. Brynskov J, Freund L, Rasmussen SN et al. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn’s disease. N Engl J Med. 1989a; 321: 845–50.CrossRefGoogle Scholar
  22. Brynskov J, Freund L, Ostergaard Thomsen O, Anderson CB, Norby Rasmussen S, Binder V. Treatment of refractory ulcerative colitis with cyclosporine enemas. Lancet. 1989; 1: 721–722.PubMedCrossRefGoogle Scholar
  23. Brynskov J, Freund L, Rasmussen SN et al. Final report on a placebo-controlled, double-blind, randomized, multicenter trial of cyclosporin treatment in active chronic Crohn’s disease. Scand J Gastroenterol. 1991; 26: 689–95.PubMedCrossRefGoogle Scholar
  24. Brynskov J, Freund L, Campanini MC, Kampmann JP. Cyclosporin pharmacokinetics after intravenous and oral administration in patients with Crohn’s disease. Scand J Gastroenterol. 1992; 27: 961–7.PubMedCrossRefGoogle Scholar
  25. Burke DA, Axon ATR, Clayden SA et al. The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 1990; 4: 123–9.PubMedCrossRefGoogle Scholar
  26. Campieri M, Lanfranchi GA, Bazzocchi G, Brignola C, Sarti F. Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet. 1981; 2: 270–1.PubMedCrossRefGoogle Scholar
  27. Campieri M, De Franchis R, Porro GB, Ranzi T, Brunetti G, Barbara L. Mesalamine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis: a randomized controlled trial. Scand J Gastroenterol. 1990a; 25: 663–8.PubMedCrossRefGoogle Scholar
  28. Campieri M, Gionchetti P, Belluzzi A et al. Role of rectal formulations: enemas. Scand J Gastroenterol. 1990b; 25 (Supp1.172): 63–5.CrossRefGoogle Scholar
  29. Campieri M, Gionchetti P, Belluzzi A et al. Topical treatment with 5-aminosalicylic acid in distal ulcerative colitis by using a new suppository preparation: a double-blind placebo controlled trial. Int J Colorectal Dis. 1990c; 5: 79–81.PubMedCrossRefGoogle Scholar
  30. Campieri M, Bianchi P, Bianchi Porro G et al. Therapeutic evaluation of mesalamine foam (Asacol) versus mesalamine enema in the treatment of distal ulcerative colitis. Gastroenterology. 1991a; 100: A200.Google Scholar
  31. Campieri M, Gionchetti P, Belluzzi A et al. Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. Gut. 1991b; 32: 929–31.PubMedCrossRefGoogle Scholar
  32. Canadian Inflammatory Bowel Disease Study Group. Oral budesonide in active Crohn’s disease: interim report of a placebo controlled randomized trial. Immunol Microbiol Inflam Disorders. 1993; A675.Google Scholar
  33. Canadian Inflammatory Bowel Disease Study Group. Budesonide 9 or 15 mg rapidly improves quality of life (qol) in active Crohn’s disease. J Irvin Gut (In press).Google Scholar
  34. Caprilli R, Andreoli A, Capurso L et al and the Gruppo Italiano Per Lo Studio Del Colon E Del Retto (Gisc). Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of postoperative recurrence of Crohn’s disease. Aliment Pharmacol Ther. 1994; 8: 35–43.PubMedCrossRefGoogle Scholar
  35. Caravo M, Camilo ME, Pinto Correia J. Nutritional support in Crohn’s disease: which route? Am J Gastroenterol. 1991; 86: 317–21.Google Scholar
  36. Christensen LA, Fallingborg J, Abildgaard K et al. Topical and systemic availability of 5aminosalicylate: comparisons of 3 controlled release preparations in man. Aliment Pharmacol Ther. 1990; 4: 523–33.PubMedCrossRefGoogle Scholar
  37. Collawn C, Rubin P, Perez N et al. Phase II study of the safety and efficacy of a 5-lipoxygenase inhibitor in patients with ulcerative colitis. Am J Gastroenterol. 1992; 87: 342–6.PubMedGoogle Scholar
  38. Cominelli F, Nast CCC, Duchini A, Lee M. Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. Gastroenterology. 1992; 103: 65–71.PubMedGoogle Scholar
  39. Connell AM, Lennard-Jones JE, Misiewicz JJ, Baron JH, Avery-Jones FA. Comparison of acetarsol and prednisolone-21-phosphate suppositories in the treatment of idiopathic proctitis. Lancet. 1965; 1: 238–9.PubMedCrossRefGoogle Scholar
  40. Connell WR, Kamm MA, Lennard-Jones JE, Ritchie JD. Bone marrow toxicity from azathioprine in inflammatory bowel disease: experience from 1963 patient years of therapy. Gut. 1992;33(Suppl.l):S10(abstr.).Google Scholar
  41. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut. 1993; 34: 1081–5.PubMedCrossRefGoogle Scholar
  42. Courtney MG, Nunes DP, Bergin CF et al. Randomised comparison of olsalazine and mesalamine in prevention of relapses in ulcerative colitis. Lancet. 1992; 339: 1279–81.PubMedCrossRefGoogle Scholar
  43. D’Arienzo A, Panarese A, Darmiento FP et al. 5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial. Am J Gastroenterol. 1990; 85: 1079–82.PubMedGoogle Scholar
  44. Danielsson A, Hellers G, Lyrenas E et al. A controlled randomized trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Scand J Gastroenterol. 1987; 22: 987–92.PubMedCrossRefGoogle Scholar
  45. Danielsson A, Lofberg R, Persson T et al. A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis. Scand J Gastroenterol. 1992; 27: 9–12.PubMedCrossRefGoogle Scholar
  46. Danielsson A, Edsbacker S, Lofberg R et al. Pharmacokinetics of budesonide enema in patients with distal ulcerative colitis of proctitis. Aliment Pharmacol Ther. 1993; 7: 401–7.PubMedCrossRefGoogle Scholar
  47. Danish 5-ASa Group. Topical 5-aminosalicylic acid versus prednisolone in ulcerative proctosigmoiditis: a randomized double-blind multicenter trial. Dig Dis Sci. 1987; 2: 598–602.CrossRefGoogle Scholar
  48. Danish Budesonide Study Group. Budesonide enema in distal ulcerative colitis: a randomized dose-response trial with prednisolone enema as positive control. Scand J Gastroenterol. 1991; 26: 1225–30.CrossRefGoogle Scholar
  49. Deusch K, Reiter C, Mauthe B et al. Chimeric monoclonal anti-CD4 antibody therapy proves effective for treating inflammatory bowel disease. Gastroenterology. 1992; 102: A615.Google Scholar
  50. De Vos M, Verdievel H, Schoonjans R, Praet M, Bogaert M, Barbier F. Concentrations of 5ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations. Gut. 1992; 33: 1338–42.PubMedCrossRefGoogle Scholar
  51. Dew MJ, Hughes P, Harris AD et al. Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid. Br Med J. 1982; 285: 1012.CrossRefGoogle Scholar
  52. Dew MJ, Harris AD, Evans N et al. Maintenance of remission in ulcerative colitis with 5aminosalicylic acid in high doses by mouth. Br Med J. 1983; 287: 23.CrossRefGoogle Scholar
  53. Dissanayake AS, Truelove SC. A controlled therapeutic trial of long-term maintenance treatment of UC with sulfasalazine. Gut. 1973; 14: 923.PubMedCrossRefGoogle Scholar
  54. Ewe K, Press AG, Singe CC et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn’s disease. Gastroenterology. 1993; 105: 367–72.PubMedGoogle Scholar
  55. Ewe K, Herfarth C, Malchow H, Jesdinsky HJ. Postoperative recurrence of Crohn’s disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial. Digestion. 1989; 42: 224–32.PubMedCrossRefGoogle Scholar
  56. Feagan BE, McDonald JWD, Rochon J et al. Low-dose cyclosporine for the treatment of Crohn’s disease. N Engl J Med. 1994a; 330: 1846–51.PubMedCrossRefGoogle Scholar
  57. Feagan BG, Rochon J, Fedorak RN et al. Methotrexate for the treatment of Crohn’s disease. In press, 1994b.Google Scholar
  58. Feurle GE, Theuer D, Volasco S et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: A randomized double-blind trial. Gut. 1989; 30: 1354.PubMedCrossRefGoogle Scholar
  59. Fiorentini MT, Fracchia M, Galatola G, Barlotta A, Delapierre M. Acute pancreatitis during oral 5-aminosalicylic therapy. Dig Dis Sci. 1990; 35: 1180–2.PubMedCrossRefGoogle Scholar
  60. Fischer SH, Levine DS, Haggett RC. Immunoglobulin therapy for active and extensive idiopathic ulcerative colitis and Crohn’s colitis. Gastroenterology. 1990; 98: A170.Google Scholar
  61. Florent C, Cortot A, Quandale P et al. Placebo-controlled trial of Claversal® in the prevention of early endoscopic relapse after `curative’ resection for Crohn’s disease. Gastroenterology. 1992; 102: A623.Google Scholar
  62. Gaginella TS, Walsh RE. Sulfasalazine: multiplicity of action. Dig Dis Sci. 1992;37;801–12. Galandiuk S, Oneill M, McDonald P, Fazio VW, Steigerr E. A century of home parenteral nutrition for Crohn’s disease. Am J Surg. 1990; 159: 540–5.Google Scholar
  63. Gendre JP, Mary JY, Florent C et al and the Groupe D’Etude Therapeutique Des Affections Inflammatories Digestives. Oral mesalamine (Pentasa) as maintenance treatment in Crohn’s disease: a multicenter placebo-controlled study. Gastroenterology. 1993; 104: 435–9.PubMedGoogle Scholar
  64. Gendre JP, Mary JY, Florent C et al. Does pentasa prevent relapses in quiescent Crohn’s disease? A multicenter placebo-controlled trial (161 patients). Gastroenterology. 1990; 98: A171.Google Scholar
  65. Gertner DJ, Rampton DS, Stevens TRJ, Lennard-Jones JE. Verapamil inhibits in-vitro leukotriene B4 release by rectal mucosa in active ulcerative colitis. Aliment Pharmacol Ther. 1992; 6: 163–8.PubMedCrossRefGoogle Scholar
  66. Giaffer MH, Cann P, Holdsworth CD. Long-term effects of elemental and exclusion diets for Crohn’s disease. Aliment Pharmacol Ther. 1991; 5: 115–25.PubMedCrossRefGoogle Scholar
  67. Giaffer MH, Holdsworth CD, Lennard-Jones JE. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/d. Aliment Pharmacol Ther. 1992; 6: 479–85.PubMedCrossRefGoogle Scholar
  68. Giaffer MH, North G, Holdsworth CD. Controlled trial of polymeric versus elemental diet in treatment of active Crohn’s disease. Lancet. 1990; 335: 816–19.PubMedCrossRefGoogle Scholar
  69. Gibson GR, Whitacre EB, Ricotti CA. Colitis induced by nonsteroidal anti-inflammatory drugs: report of four cases and review of the literature. Arch Intern Med. 1992; 152: 625–32.PubMedCrossRefGoogle Scholar
  70. Ginsberg AL, David ND, Nochomovitz LE. Placebo-controlled, double-blind trial of oral 4aminosalicylic acid in ulcerative colitis. Gastroenterology. 1990; 98: A172.Google Scholar
  71. Gorard DA, Hunt JB, Payne-James JJ et al. Initial response and subsequent course of Crohn’s disease treated with elemental diet or prednisolone. Gut. 1993; 34: 1198–202.PubMedCrossRefGoogle Scholar
  72. Gramlich LM, Barley RB, Intravenous (IV) cyclosporine in refractory Crohn’s disease for remission induction. Trends in Inflammatory Bowel Disease Therapy, Victoria, 6–9 April, Poster 15, 1994.Google Scholar
  73. Green JRB, Swan CHJ, Rowlinson A et al. Short report: Comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Aliment Pharmacol Ther. 1992; 6: 647–52.PubMedCrossRefGoogle Scholar
  74. Greenfield SM, Punchard NA, Teare JP, Thompson RPH. Review article: The mode of action of the aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther. 1993; 7: 369–83.PubMedCrossRefGoogle Scholar
  75. Habal FM, Hui G, Greenberg GR. Oral 5-aminosalicylic acid for inflammatory bowel disease in pregnancy: Safety and clinical course. Gastroenterology. 1993; 105: 1057–60.PubMedGoogle Scholar
  76. Halpern Z, Sold O, Baratz M, Konikoff F, Halak A, Gilat T. A controlled trial of beclomethasone versus betamethasone enemas in distal ulcerative colitis. J Clin Gastroenterol. 1991; 13: 38–41.PubMedCrossRefGoogle Scholar
  77. Hanauer S, Schwartz J, Roufail W et al. Dose-ranging study of oral mesalamine capsule (Pentasa) for active ulcerative colitis. Gastroenterology. 1986; 96: A85 (abstr.).Google Scholar
  78. Hanauer SB, Krawitt EL, Ropbinson et al. Long-term management of Crohn’s disease with mesalamine capsules (Pentasa®). Am J Gastroenterol. 1988; 88: 1343.Google Scholar
  79. Hanauer S, Beschcars L, Wilkinson C et al. Induction of remission in a dose-ranging study of oral mesalamine capsules. Gastroenterology. 1990;98:A 174.Google Scholar
  80. Hanauer SB. Sulfasalazine vs. steroids in Crohn’s disease: David vs Goliath [editorial]? Gastroenterology. 1991; 101: 1130–1.PubMedGoogle Scholar
  81. Hanauer ST, Krawitt EL, Robinson M, Rick GG, Safdi MA and the Pentasa ® Crohn’s Disease Compassionalt Use Study Group. Long-term management of Crohn’s disease with mesalamine capsules (Pentasa®). Am J Gastroenterol. 1993; 88: 1343.PubMedGoogle Scholar
  82. Hawthorne AB, Daneshmend TJ, Hawkey CJ et al. Treatment of ulcerative colitis with fish oil supplementation: A prospective 12 month randomized controlled trial. Gut. 1992a; 33: 922–8.PubMedCrossRefGoogle Scholar
  83. Hawthorne AB, Logan RFA, Hawkey CJ et al. Randomized controlled trial of azathioprine withdrawal in ulcerative colitis. Brit Med J. 1992b; 305: 20–2.PubMedCrossRefGoogle Scholar
  84. Hemphill DI, Greenberg GR, Steinhart AH. Sulfasalazine and mesalazine for maintenance therapy of Crohn’s disease: a meta-analysis. Clin Inv Med. 1993; 16: B46.Google Scholar
  85. Hetzel DJ, Shearman DJ, Labrooy J et al. Olsalazine in the treatment of active ulcerative colitis. A placebo-controlled trial and assessment of drug deposition. J Gastroenterol Hepatol. 1986; 1: 257.CrossRefGoogle Scholar
  86. Holdstock GE, Fischer JA, Kembilin LT, Leohrig T. Plasmapheresis in Crohn’s disease. Digestion. 1979; 19: 197–201.PubMedCrossRefGoogle Scholar
  87. International Mesalamine study Group. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn’s disease. Aliment Pharmacol Ther. 1990; 4: 55–64.CrossRefGoogle Scholar
  88. Ireland A, Mason CH, Jewell DP. Controlled trial comparing olsalazine and sulfasalazine for the maintenance treatment of ulcerative colitis. Gut. 1988; 29: 835–7.PubMedCrossRefGoogle Scholar
  89. Irvine EJ, Marshall JK. A meta-analysis of topical ASAs for distal ulcerative colitis (UC). Trends in Inflammatory Bowel Disease Therapy, Victoria, 6–9 April, Post 21, 1994.Google Scholar
  90. Jarnerot G, Rolny P, Sandber-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology. 1985; 89: 1005–13.PubMedGoogle Scholar
  91. Jarnerot G, Lennard-Jones J, Bianchi-Porro G, Brynskov J, Campieri M, Present D. Medical treatment of refractory distal ulcerative colitis. Gastroenterol Int. 1991; 4: 93–8.Google Scholar
  92. Jewell DP, Caprilli R, Mortensen N, Nicholls RJ, Wright JP. Indications and timing of surgery for severe ulcerative colitis. Gastroenterol Int. 1991; 4: 161–4.Google Scholar
  93. Katz J. Treatment of Crohn’s disease with 5-ASA. Am J Gastroenterol. 1993; 88: 1315–17.PubMedGoogle Scholar
  94. Killerich S, Ladefoged K, Rannem T, Ranlov PJ. The Danish Olsalazine Study Group: Prophylactic effects of olsalazine v sulfasalazine during 12 months maintenance treatment of ulcerative colitis. Gut. 1992; 33: 252–5.CrossRefGoogle Scholar
  95. Kirsner JB, Shorter RG. Preface. In: Kirsner JB, Shorter RG, editors. Inflammatory bowel disease. Philadelphia: Lea and Febiger, 1975.Google Scholar
  96. Kitano A, Matsumoto T, Nakamura S et al. New treatment of ulcerative colitis with K-76. Dis Colon Rectum. 1992; 35: 560–7.PubMedCrossRefGoogle Scholar
  97. Klein M, Binder HJ, Mitchell M, Aaronson R, Spiro H. Treatment of Crohn’s disease with azathioprine: a controlled evaluation. Gastroenterology. 1974; 66: 916–22.PubMedGoogle Scholar
  98. Korelitz BI, Present BH. Shortcomings of the national Crohn’s disease study: the exclusion of azathioprine without adequate trial. Gastroenterology. 1981; 80: 193–200.PubMedGoogle Scholar
  99. Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball Ti, Wilske RR. Methotrexate induces clinical and histological remission in patients with refractory inflammatory bowel disease. Ann Intern Med. 1989; 110: 353–6.PubMedGoogle Scholar
  100. Kozarek RA, Patterson DJ, Botoman VA, Ball Ti, Gelfand MD. Methotrexate (MTX) use in inflammatory bowel disease (IBD) patients who have failed azathioprine (AZ) or 6mercaptupurine (6-MP). Gastroenterology. 1991; 100: A222.Google Scholar
  101. Kulerich S, Ladefoged K, Rannem T, Ranlov PJ, The Danish Olsalazine Study Group: Prophylactic effects of olsalazine v sulfasalazine during 12 months maintenance treatment of ulcerative colitis. Gut. 1992; 33: 252–5.CrossRefGoogle Scholar
  102. Kusunoki M, Moelein G, Shoji Y et al. Steroid complications in patients with ulcerative colitis. Dis Colon Rectum. 1992; 35: 1003–9.PubMedCrossRefGoogle Scholar
  103. Lamers C, Meijer J, Engels L et al. Comparative study of the topically acting glucocorticosteroid budesonide and 5-aminosalicylic acid enema therapy of proctitis and proctosigmoiditis. Am J Gastroenterol. 1991; 100: A223.Google Scholar
  104. Langholz E, Brynskov J, Bendtzen K, Vilien M, Binder V. Treatment of Crohn’s disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin. Aliment Pharmacol Ther. 1992; 6: 495–502.PubMedCrossRefGoogle Scholar
  105. Lashner BA, Hanauer SB, Silverstein MD. Testine nicotine gum for ulcerative colitis patients. Experience with single patient trials. Dig Dis Sci. 1990; 35: 827–32.PubMedCrossRefGoogle Scholar
  106. Laursen LS, Stokolm M, Bukhave K, Rask-Madsen J, Lauritsen K. Disposition of 5aminosalicylic acid by olsalazine and three mesalamine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut. 1990; 31: 1271–6.CrossRefGoogle Scholar
  107. Lechin F, van der Kijs B, Insaysti CL et al. Treatment of ulcerative colitis with clonidine. J Clin Pharmacol. 1985; 25: 19–26.Google Scholar
  108. Leddin DJ, VeldLuyzenNanZanten S, Sidorow JJ, Stewart J, Tripathi D, Williams CN. Colectomy following treatment of Crohn’s colitis with cyclosporine A (CyA). Trends in Inflammatory Bowel Disease Therapy, Victoria, 6–9 April, Poster 33, 1994.Google Scholar
  109. Lemann M, Bonhomme P, Bitoun A, Messing B, Modigliani R, Rambaud JC. Treatment of Crohn’s disease with azathioprine or 6-mercaptopurine: retrospective study in 126 patients [in French]. Gastroenterol Clin Biol. 1990; 14: 548–54.PubMedGoogle Scholar
  110. Lennard-Jones JE. Azathioprine and 6-mercaptopurine have a role in the treatment of Crohn’s disease. Dig Dis Sci. 1981; 26: 364–8.PubMedCrossRefGoogle Scholar
  111. Levine DS, Fischer SH, Christie DI, Haggitt RC, Ochs HD. Intravenous immunoglobulin therapy for active, extensive, and medically refractory idiopathic ulcerative or Crohn’s colitis. Am J Gastroenterol. 1992; 87: 91–100.PubMedGoogle Scholar
  112. Lichtenstein JE. Inflammatory conditions of the stomach and duodenum. Radiol Clin N Am. 1993; 31: 1315–33.PubMedGoogle Scholar
  113. Lichter S, Present DH, Kornbluth A et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994; 330: 1841–5.CrossRefGoogle Scholar
  114. Lichtiger S, Present DH. Cyclosporine in treatment of severe active ulcerative colitis. Lancet. 1990; 336: 16–19.PubMedCrossRefGoogle Scholar
  115. Linn FV, Peppercorn MA. Drug therapy for inflammatory bowel disease: Part I. Am J Surg. 1992; 164: 85–9.PubMedCrossRefGoogle Scholar
  116. Lobo Ai, Foster PN, Burke DA, Johnston D, Axon ATR. The role of azathioprine in the management of ulcerative colitis. Dis Colon Rectum. 1990; 33: 374–7.CrossRefGoogle Scholar
  117. Lobo AJ, Juby LD, Rothwell J, Poole TW, Axon ATR. Long-term treatment of Crohn’s disease with cyclosporine: the effect of a very low dose on maintenance of remission. J Clin Gastroenterol. 1991; 13: 42–5.PubMedCrossRefGoogle Scholar
  118. Lochs H, Steinhardt HJ, Klaus-Wentz B et al. Comparison of enteral nutrition and drug treatment in active Crohn’s disease. Gastroenterology. 1991; 101: 881–8.PubMedGoogle Scholar
  119. Löfberg R, Ostergaard-Thomsen O, Langholtz E et al. Budesonide versus prednisolone enema in active distal ulcerative colitis. A comparative eight week study. Gut. 1993; 34 (Suppl.): 41.CrossRefGoogle Scholar
  120. Löfberg R, Rutgeerts P, Malchow H et al. Budesonide CIR for maintenance of remission in ileocecal Crohn’s disease. A European multicenter placebo controlled trial for 12 months. Gastroenterology. 1994; 106: A722.Google Scholar
  121. Malchow H, Ewe K, Brandes JW et al. European Cooperative Crohn’s Disease Study (ECCDS); results of drug treatment. Gastroenterology. 1984; 86: 249–66.PubMedGoogle Scholar
  122. Mantzaris G, Hatzis A, Kontogiannis P, Triadaphyllou G. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis.Google Scholar
  123. Martin F, Sutherland L, Beck IT et al. Oral 5-ASA versus prednisone in short term treatment of Crohn’s disease: a multicenter controlled trial. Can J Gastroenterol. 1990; 4: 452–7.Google Scholar
  124. Mayer L, Schar DB, Present DH et al. Randomized double-blind placebo-controlled trial of hydroxychloroquine (Plaquenil) in the treatment of ulcerative colitis. Gastroenterology. 1992; 102: A661.Google Scholar
  125. Mayer L, Sachar DB. Efficacy of chloroquine in the treatment of inflammatory bowel disease. Gastroenterology. 1988; 984: A293.Google Scholar
  126. McIntyre PB, Rodrigues CA, Lennard-Jones JE et al. Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulfasalazine. Aliment Pharmacol Ther. 1988; 2: 237–43.PubMedCrossRefGoogle Scholar
  127. McLeod RS, Wolff BG, Steinhart H et al. Decreased recurrence following surgery for Crohn’s disease (CD) using Salofalk 5-ASA tablets 3 gm/day. Trends in Inflammatory Bowel Disease Therapy, Victoria, 6–9 April 1994.Google Scholar
  128. Mehta RP. Acute intestinal nephritis due to 5-aminosalicylic acid. Can Med Assoc J. 1990; 143: 1031–2.Google Scholar
  129. Messori A, Brignola C, Trallori G et al. Effectiveness of 5-aminosalicylic acid (5-ASA) for maintaining remission in patients with Crohn’s disease: a meta-analysis. Am J Gastroenterol. 1994; 89: 692–8.PubMedGoogle Scholar
  130. Meyers S, Sachar DB, Present DH et al. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomised, placebo-controlled, double-blind, dose-ranging clinical trial. Gastroenterology. 1987; 934: 1255.Google Scholar
  131. Miglioli M, Barbara L, Di Febo G et al. Topical administration of 5-aminosalicylic acid: a therapeutic proposal for the treatment of pouchitis (letter). N Engl J Med. 1989; 320: 257.PubMedGoogle Scholar
  132. Miglioli M, Bianchi Porro G, Brunetti G, Sturniolo GC. Oral delayed-release mesalamine in the treatment of mild ulcerative colitis: a dose ranging study. Eur J Gastroenterol Hepatol. 1990a; 2: 2299.Google Scholar
  133. Miglioli M, Porro GB, Brunetti G, Sturniolo GC. Oral delayed-release mesalamine in the treatment of mild ulcerative colitis: a dose ranging study. Eur J Gastroenterol Hepatol. 1990b; 2: 229.Google Scholar
  134. Mihida YR, Jewell DP. Slow-release 5-aminosalicylic acid (Pentasa®) for the treatment of active Crohn’s disease. Digestion. 1990; 45: 88–92.CrossRefGoogle Scholar
  135. Miner P, Schwartz J, Aora S et al. Maintenance of remission in ulcerative colitis patients with controlled-release mesalamine capsules (Pentasa®). Gastroenterology. 1992; 102: A266.Google Scholar
  136. Modigliani R, Mary JY, Simon JF et al. Clinical, biological, and endoscopic picture of attacks of Crohn’s disease: evolution on prednisolone. Gastroenterology. 1990; 98: 811–18.PubMedCrossRefGoogle Scholar
  137. Mulder CJJ, Tytgat GNJ, Weterman IT et al. Double-blind comparison of slow-release 5aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology. 1988; 95: 1449–53.PubMedGoogle Scholar
  138. Nakshabendi IM, Duncan A, Russell RI. Is Asacol as effective as sulfasalazine in maintaining remission of Crohn’s disease and ulcerative colitis? Postgrad Med J. 1992; 68: 189–91.PubMedCrossRefGoogle Scholar
  139. O’Brien JJ, Bayless TM, Bayless JA. Use of azathioprine of 6-mercaptopurine in the treatment of Crohn’s disease. Gastroenterology. 1991; 101: 39–46.PubMedGoogle Scholar
  140. O’Donoghue DP, Dawson AM, Powell-Tuck J, Brown RL, Lennard-Jones JE. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn’s disease. Lancet. 1978; 2: 955–7.PubMedCrossRefGoogle Scholar
  141. O’Morain CA. Does nutritional therapy in inflammatory bowel disease have a primary or an adjunctive role? Scand J Gastroenterol. 1990; 25 (Suppl.172): 29–34.CrossRefGoogle Scholar
  142. Oliason G, Sjodhal R, Tagesson C. Glucocorticoid treatment in ileal Crohn’s disease: relief of symptoms but not of endoscopically viewed inflammation. Gut. 1990; 31: 325–8.CrossRefGoogle Scholar
  143. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn’s disease: a meta-analysis. Trends in Inflammatory Bowel Disease Therapy, Victoria, 6–9 April, Post 8, 1994.Google Scholar
  144. Perrault H, Greseth JLM, Tremaine WJ. 6-Mercaptopurine therapy in selected cases of corticosteroid-dependent Crohn’s disease. Mayo Clin Proc. 1991; 66: 480–4.PubMedGoogle Scholar
  145. Prantera C, Pallone F, Brunetti G, Cottone M, Miglioli M, The Italian IBD Study Group: Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn’s disease. Gastroenterology. 1992; 103: 363–8.PubMedGoogle Scholar
  146. Present DH. 6-Mercaptopurine and other immunosuppressive agents in the treatment of Crohn’s disease and ulcerative colitis. Gastroenterol Clin N Am. 1989; 18: 57–71.Google Scholar
  147. Present DH, Korelitz BI, Wisch N, Glass GL, Sachar DB, Pasternack BS. Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med. 1980; 302: 981–7.PubMedCrossRefGoogle Scholar
  148. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short-and long-term toxicity. Ann Intern Med. 1989; 111: 641–9.PubMedGoogle Scholar
  149. Ranzi T, Campanini MC, Velio P, Quarto Di Palo F, Bianchi P. Treatment of chronic proctosigmoiditis with cyclosporin enemas. Lancet. 1989; 2: 97.PubMedCrossRefGoogle Scholar
  150. Rasmussen SN, Bondesen S, Hvidberg EF et al. Amino-salicylic acid in a slow-release preparation: bioavailability, plasma level and excretion in humans. Gastroenterology. 1982; 83: 1062–71.PubMedGoogle Scholar
  151. Rasmussen SN, Lauritsen K, Tage-Jensen U et al. 5-aminosalicylic in the treatment of Crohn’s disease. A 16-week double-blind, placebo-controlled, multicenter study with Pentasa®. Scand J Gastroenterol. 1987; 22: 877.PubMedCrossRefGoogle Scholar
  152. Record CO, Macrae K. Mesalamine versus olsalazine for prophylaxis of ulcerative colitis relapse. Lancet. 1992; 340: 1468.PubMedCrossRefGoogle Scholar
  153. Rhodes J, Bainton D, Beck P, Campbell H. Controlled trial of azathioprine in Crohn’s disease. Lancet. 1971; 2: 1273–6.PubMedCrossRefGoogle Scholar
  154. Rigaud D, Cosnes J, Le Quintrec Y, Renne E, Gendre JP, Mignon M. Controlled trial comparing two types of enteral nutrition in treatment of active Crohn’s disease: elemental polymeric diet. Gut. 1991; 32: 1492–7.PubMedCrossRefGoogle Scholar
  155. Rijk MCM, Van Hogezand RA, Van Schaik A, Van Tongeren JHM. Disposition of 5aminosalicylic acid from 5-aminosalicylic acid-delivering drugs during accelerated intestinal transit in healthy volunteers. Scand J Gastroenterol. 1989; 24: 1179–85.PubMedCrossRefGoogle Scholar
  156. Rijk MCM, Van Hogezand RA, Van Lier HJJ et al. Sulfasalazine and prednisone compared with sulfasalazine for treating active Crohn’s disease: a double-blind, randomized, multicenter trial. Ann Intern Med. 1991a; 114: 445–50.PubMedGoogle Scholar
  157. Rijk MCM, Tongeren JHM. The relapse preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission. Gastroenterology. 1991b; 100: A243.Google Scholar
  158. Rijk MCM, Van Lier HJJ, Van Tongeren JHM. Relapse preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: a prospective, double-blind, randomized multicenter study. Am J Gastroenterol. 1992; 87: 438–42.PubMedGoogle Scholar
  159. Riley SA, Turnberg LA. Sulfasalazine and the aminosalicylates in the treatment of inflammatory bowel disease. Q J Med. 1990; 278: 551–62.Google Scholar
  160. Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA. Comparison of delayed-release 5-aminosalicylic acid (mesalamine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology. 1988a; 94: 1383–8.PubMedGoogle Scholar
  161. Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA. Comparison of delayed-release 5-aminosalicylic acid (mesalamine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology. 1988b; 94: 1449.Google Scholar
  162. Riley SA, Tavares IA, Bishai PM, Bennet A, Mani V. Mesalamine release from coated tablets: effect of dietary fibre. Br J Clin Pharmacol. 1991; 32: 248–50.PubMedGoogle Scholar
  163. Robinson M, Gilrick G, Balart L et al. Olsalazine in the treatment of mild to moderate ulcerative colitis. Gastroenterology. 1988; 94: A381.Google Scholar
  164. Rosenberg JL, Levin B, Wall AJ, Kirsner JB. A controlled trial of azathioprine in Crohn’s disease. Am J Dig Dis. 1975; 20: 721–6.PubMedCrossRefGoogle Scholar
  165. Rosenberg W, Ireland A, Jewell D. High-dose methylprednisolone in the treatment of active ulcerative colitis. J Clin Gastroenterol. 1990; 12: 40–1.PubMedCrossRefGoogle Scholar
  166. Rutgeerts P. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulfasalazine for maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 1989; 3: 183.PubMedCrossRefGoogle Scholar
  167. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. 1990; 99: 956–63.PubMedGoogle Scholar
  168. Rutgeerts P, Geboes K, Vantrappen G et al. Rifabutin and ethambutol do not help recurrent Crohn’s disease in the neoterminal ileum. J Clin Gastroenterol. 1992; 15: 24–8.PubMedCrossRefGoogle Scholar
  169. Rutgeerts P, Lofberg R, Malchow H et al. Budesonide versus prednisolone for the treatment of active ileocecal Crohn’s disease: a European multicenter trial. Gastroenterology. 1993; 104A: 772.Google Scholar
  170. Ryder SD, Walker RJ, Jones H, Rhodes JM. Rectal bismuth subsalicylate as therapy for ulcerative colitis. Aliment Pharmacol Ther. 1990; 4: 333–8.PubMedCrossRefGoogle Scholar
  171. Salomon P, Kornbluth AA, Janowitz HD. Treatment of ulcerative colitis with fish oil n-3omega-fatty acid: an open trial. J Clin Gastroenterol. 1990; 12: 157–61.PubMedCrossRefGoogle Scholar
  172. Salomon P, Kornbluth A, Aisennberg J et al. How effective are current drugs for Crohn’s disease? J Clin Gastroenterol. 1992; 14: 211.PubMedCrossRefGoogle Scholar
  173. Sandberg-Gertzen H, Jarnerot G, Kraaz W. Azodisal sodium in the treatment of ulcerative colitis: a study of tolerance and relapse-prevention properties. Gastroenterology. 1986; 90: 1024–30.PubMedGoogle Scholar
  174. Sandborn WJ, Tremaine WJ. Cyclosporine treatment of inflammatory bowel disease. Mayo Clin Proc. 1992; 67: 981–90.PubMedGoogle Scholar
  175. Sandborn WJ, Strong RM, Forland SC, Chase RL, Cutler RE. Cyclosporin pharmacokinetics and colon tissue concentration after oral administration of retention enema in man. Gastroenterology. 1990; 98: A202.Google Scholar
  176. Sandborn WJ, Goldman DH, Lawson GM, Perrault J. Measurement of colonic tissue cyclosporine concentration in children with severe ulcerative colitis. J Pediatr Gastroenterol Nutr. 1992; 15: 125–9.PubMedCrossRefGoogle Scholar
  177. Sandborn WJ, Tremaine WJ, Schroeder KW et al. Cyclosporine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis. Am J Gastroenterol. 1993; 88: 640–5.PubMedGoogle Scholar
  178. Sandberg-Gertzen H, Jarnerot G, Kraaz W. Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-preventing properties. Gastroenterology. 1986; 90: 1024.PubMedGoogle Scholar
  179. Scheppach W, Sommer H, Kirchner T et al. Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology. 1992; 103: 51–6.PubMedGoogle Scholar
  180. Schreiber S, Howaldt S, Reinecker HC et al. Maintenance treatment of Crohn’s disease: comparative study of 4-aminosalicylic acid and 5-aminosalicylic acid (Claversal®) slow release tablets. Gastroenterology. 1992; 102: A692.Google Scholar
  181. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med. 1986; 217: 1625–9.Google Scholar
  182. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med. 1987; 317: 1625–9.PubMedCrossRefGoogle Scholar
  183. Scrivusta BD, Russell MAN, Masterson JG. Transdermal nicotine in ulcerative colitis. 1991; 100: A252.Google Scholar
  184. Selby WS, Barr GD, Ireland A et al. Olsalazine in active ulcerative colitis. Br Med J. 1985; 291: 1373.CrossRefGoogle Scholar
  185. Senagore AJ, Mackeigan JM, Scheider M, Ebrom S. Short-chain fatty acid enemas: a cost effective alternative in the treatment of nonspecific proctosigmoiditis. Dis Colon Rectum. 1992; 35: 923–7.PubMedCrossRefGoogle Scholar
  186. Singleton JW. Azathioprine has a very limited role in the treatment of Crohn’s disease. Dig Dis Sci. 1982; 26: 368–71.CrossRefGoogle Scholar
  187. Singleton JW, Law DH, Kelley MI, Mekhjian HS, Sturdevant RAL. National Cooperative Crohn’s Disease Study: adverse reactions to study drugs. Gastroenterology. 1979; 77: 870–82.PubMedGoogle Scholar
  188. Singleton JW, Hanauer SB, Gitnick GL et al and the Pentasa Crohn’s Study Group. Mesalamine capsules for the treatment of active Crohn’s disease: results of a 16-week trial. Gastroenterology. 1993; 104: 1293–300.PubMedGoogle Scholar
  189. Sitzmann JV, Converse RL Jr, Bayless TM. Favourable response to parenteral nutrition and medical therapy in Crohn’s colitis. Gastroenterology. 1990; 99: 1647–52.PubMedGoogle Scholar
  190. Sninsky CA, Cort DH, Shanahan F et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis: a multicenter study. Ann Intern Med. 1991; 115: 350–5.PubMedGoogle Scholar
  191. Steinhart AH, Baker JP, Brezezinski A, Prokipchuc EJ. Azathioprine therapy in chronic ulcerative colitis. J Clin Gastroenterol. 1990; 12: 271–5.PubMedCrossRefGoogle Scholar
  192. Stenson WF, Lauritsen K, Laursen LS et al. A clinical trial of Zileuton, a specific inhibitor of 5-lipoxygenase, in ulcerative colitis. Gastroenterology. 1991; 100: A253.Google Scholar
  193. Stenson WF, Cort D, Rodgers J et al. Dietary supplementation with fish oil in ulcerative colitis. Ann Intern Med. 1992; 115: 609–14.Google Scholar
  194. Sturdevant RAL, Singleton JW, Deren JJ, Law DH, McCleery JL. Azathioprine-related pancreatitis in patients with Crohn’s disease. Gastroenterology. 1979; 77: 883–86.PubMedGoogle Scholar
  195. Summers WRW, Switz DM, Sessions JT et al. National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology. 1979; 77: 847–69.PubMedGoogle Scholar
  196. Sutherland LR. 5-Aminosalicylates for prevention of recurrence in patients with Crohn’s disease: time for a reappraisal [editorial]? J Clin Gastroenterol. 1991;13:5–7.Google Scholar
  197. Sutherland LR, Godet PG. Pharmacologic treatment of inflammatory bowel disease. Can Ther. 1994 (In press).Google Scholar
  198. Sutherland LR, Ramcharan S, Bryant H, Fick G. Effect of cigarette smoking on recurrence of Crohn’s disease. Gastroenterology. 1990a; 98: 1123–8.PubMedGoogle Scholar
  199. Sutherland LR, Robinson M, Onstad G et al. A double-blind, placebo-controlled multicentre study of the efficacy and safety of 5-aminosalicylic acid (5-ASA) tablets in the treatment of ulcerative colitis. Falk Symposium Foundation, Freiburg, Germany, 1990b, p. 45.Google Scholar
  200. Sutherland L, Singleton J, Session Jet al. Double-blind, placebo-controlled trial of metronidazole in Crohn’s disease. Gut. 1991; 32: 1071–75.PubMedCrossRefGoogle Scholar
  201. Sutherland LR, May GR, Schaeffer EA. Sulfasalazine revisited: a metaanalysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med. 1993; 118: 540.PubMedGoogle Scholar
  202. Teahon K, Bjarnason I, Pearson M, Levi AJ. Ten years’ experience with an elemental diet in the management of Crohn’s disease. Gut. 1990; 31: 1133–7.PubMedCrossRefGoogle Scholar
  203. Teahon K, Smethurst P, Pearson M, Levi AJ, Bjarnason I. The effect of elemental diet on intestinal permeability and inflammation in Crohn’s disease. Gastroenterology. 1991; 101: 84–9.PubMedGoogle Scholar
  204. Thomson ABR. Review article: new developments in the use of 5-aminosalicylic acid in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 1991; 5: 449–70.PubMedCrossRefGoogle Scholar
  205. Thomson ABR, International Mesalazine Study Group. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission in inactive Crohn’s disease. Aliment Pharmacol Ther. 1990; 4: 55.Google Scholar
  206. Tremaine WJ. Maintenance of remission in Crohn’s disease: is 5-aminosalicylic acid the answer? Gastroenterology. 1992; 103: 694–704.PubMedGoogle Scholar
  207. Tripathi RC, Kirschner BS, Kipp M et al. Corticosteroid treatment for inflammatory bowel disease in pediatric patients increases intraocular pressure. Gastroenterology. 1992a;102:1957–61.Google Scholar
  208. Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet. 1974a; 1: 1067–70.PubMedCrossRefGoogle Scholar
  209. Truelove SC, Jewell DPL. Intravenous regimen for severe attacks of ulcerative colitis. Lancet. 1974b; 1: 1086–8.Google Scholar
  210. Tytgat GNJ, Van Deventer SJH. Pouchitis. Int J Colon Dis. 1988; 3: 226–8.CrossRefGoogle Scholar
  211. Ursing B, Alm T, Barany F et al. A comparative study of metronidazole and sulfasalazine for active Crohn’s disease: the cooperative Crohn’s disease study in Sweden. II. Result. Gastroenterology. 1982; 83: 550–62.Google Scholar
  212. Van Hees PAM, van Elteren PH, van Lier HJJ, van Tongeren JHM. An index of inflammatory activity in patients with Crohn’s disease. Gut. 1980; 21: 279–86.PubMedCrossRefGoogle Scholar
  213. Van Hees PAM, Lier HJJ, Van Elteren PH et al. Effect of sulfasalazine in patients with active Crohn’s disease: a controlled double-blind study. Gut. 1981; 22: 404.PubMedCrossRefGoogle Scholar
  214. Vantrappen G, Rutgeerts P. Recurrence of Crohn’s disease in the neoterminal ileum after ileal resection and ileocolonic anastomosis. Verk K Acad Geneeskd Bldg. 1990; 52: 373–82.Google Scholar
  215. Verhave M, Winter HS, Grand RJ. Azathioprine in the treatment of children with inflammatory bowel disease. J Pediatr. 1990; 117: 809–14.PubMedCrossRefGoogle Scholar
  216. Williams CN. Role of rectal formulations: suppositories. Scand J Gastroenterol. 1990; 25 (Supp1.172): 60–2.CrossRefGoogle Scholar
  217. Willoughby JMT, Kumar PJ, Beckett J, Dawson AM. Controlled trial of azathioprine in Crohn’s disease. Lancet. 1971; 2: 944–7.PubMedCrossRefGoogle Scholar
  218. Winter T, Dalton HR, Merrett MN, Campbell A, Jewell DP. Cyclosporin A retention enemas in refractory distal ulcerative colitis: an open trial. Gastroenterology. I992; 102: A947.Google Scholar
  219. Wolf JL. Cipoflaxacin may be useful in Crohn’s disease. Gastroenterology. 1990; 98: A212.Google Scholar
  220. Wright JP. Factors influencing first relapse in patients with Crohn’s disease. J Clin Gastroenterol. 1992; 15: 12–16.PubMedCrossRefGoogle Scholar
  221. Wright JP, Boniface UA, Warner L. Sucralfate enemas in the treatment of ulcerative proctitis. Gastroenterology. 1992; 102: A714.Google Scholar
  222. Zaytoun AM, Cobden I, Al Mardini H, Record CO. Morphometric studies in rectal biopsy specimens from patients with ulcerative colitis: effect of oral 5-amino salicylic acid and rectal prednisolone treatment. Gut. 1991; 32: 183–7.CrossRefGoogle Scholar
  223. Zinberg J, Molinas S, Das KM. Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis. Am J Gastroenterol. 1990;85:562-6.Google Scholar

Copyright information

© Kluwer Academic Publishers and Axcan Pharma, Inc. 1994

Authors and Affiliations

  • A. B. R. Thomson

There are no affiliations available

Personalised recommendations